Risankizumab vs Ustekinumab in Patients With Crohn Disease: Trial Results

Head-to-head study compared risankizumab (Skyrizi) to ustekinumab (Stelara) in patients with moderately to severely active Crohn disease.

Related Keywords

,Crohn Disease Activity Index ,Simple Endoscopy Score ,Crohn Disease ,